Journal Article
. 1984 Oct; 3(5):475-82.

Systemic administration of interleukin-2 in humans

M T Lotze  R J Robb  S O Sharrow  L W Frana  S A Rosenberg  
  • PMID: 6334135
  •     21 citations


Twelve patients were treated in a Phase I trial of purified human interleukin-2 (IL-2) derived from the JURKAT cell line (E.I. duPont Corp., Glenolden, PA, U.S.A.). The serum half-life, toxicity, and in vivo immunologic effects of IL-2 were studied in patients with cancer unresponsive to standard therapy and in patients with acquired immunodeficiency syndrome (AIDS). Patients received 0.25, 2.5, or 25 micrograms/kg IL-2 by bolus or 24-h continuous infusion on a weekly basis for 4 weeks. The serum half-life of JURKAT IL-2 in humans was approximately 6 min. At higher doses of IL-2 a second component of clearance with a half-life of 30-120 min was found. Acute toxicity was minimal and consisted of headache (6 of 12), nausea (4 of 12), malaise (6 of 12), and fever and chills (8 of 12). No evidence of pulmonary, hematologic, or renal toxicity or any evidence of autoimmune phenomena was detected. A transient hyperbilirubinemia was seen in two patients receiving 2 mg purified IL-2. No demonstrable effect on tumors or chronic immunodeficiency (AIDS) was seen. No consistent chronic immunologic effects (natural killer or lymphokine-activated killer activity, mitogen responsiveness, total lymphocyte counts, or change in the proportion of various mononuclear cell phenotypes as defined by monoclonal antibody) were seen on a week-to-week basis during or following therapy. Acute changes in lymphokine responsiveness, the ability to generate lymphokine-activated killers, and an increase in macrophages in the mononuclear population were noted following administration of 1-2 mg IL-2.

Keywords: Acquired Immunodeficiency Syndrome; Cancer; Diseases; Drugs--administraction and dosage; Drugs--pharmacodynamics; Drugs--therapeutic use; Evaluation; Examinations And Diagnoses; Hiv Infections; Laboratory Examinations And Diagnoses; Laboratory Procedures; Neoplasms; Treatment; Viral Diseases.

Other Links

Interleukins. Clinical pharmacokinetics and practical implications.
V Bocci.
Clin Pharmacokinet, 1991 Oct 01; 21(4). PMID: 1760900
Modulation of the immune response to tumors by a novel synthetic compound, (4R)-3-benzoyl-N-[(1R)-1-phenylethyl]-4-thiazolidinecarboxamide (RS-0481).
S Kurakata, M Tomatsu, +6 authors, K Nomoto.
Cancer Immunol Immunother, 1991 Jan 01; 33(2). PMID: 1828007
Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2.
A M Eggermont, E P Steller, W Matthews, P H Sugarbaker.
Br J Cancer, 1987 Aug 01; 56(2). PMID: 2444243    Free PMC article.
Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.
P J Guillou, P C Sedman, C W Ramsden.
Cancer Immunol Immunother, 1989 Jan 01; 28(1). PMID: 2462468
The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.
S D Voss, G Weil-Hillman, +2 authors, P M Sondel.
Bull N Y Acad Med, 1989 Jan 01; 65(1). PMID: 2690996    Free PMC article.
Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells.
M Hoffman, A Mittelman, +6 authors, E Podack.
J Cancer Res Clin Oncol, 1989 Jan 01; 115(2). PMID: 2785519
Modulation of the immune response to tumors by a novel synthetic compound, N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide (CL 259,763).
B S Wang, V Ruszala-Mallon, +3 authors, F E Durr.
Cancer Immunol Immunother, 1986 Jan 01; 22(1). PMID: 2939949
Regulation of human T-lymphocyte gene expression by interleukin 2: immediate-response genes include the proto-oncogene c-myb.
C D Pauza.
Mol Cell Biol, 1987 Jan 01; 7(1). PMID: 3104767    Free PMC article.
Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by Moloney murine sarcoma virus.
S Mitsunaga, H Kimura, Y Yamaguchi, A Mikata.
Jpn J Cancer Res, 1988 Aug 01; 79(8). PMID: 3141331    Free PMC article.
In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2).
N Saijo, A Ozaki, +4 authors, A Hoshi.
J Cancer Res Clin Oncol, 1986 Jan 01; 111(3). PMID: 3488319
Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer.
R L Kradin, L A Boyle, +5 authors, J T Kurnick.
Cancer Immunol Immunother, 1987 Jan 01; 24(1). PMID: 3493073
The toxicity of recombinant human interleukin-2 in rats following intravenous infusion.
Y L Matory, A E Chang, +3 authors, S A Rosenberg.
J Natl Med Assoc, 1987 May 01; 79(5). PMID: 3495666    Free PMC article.
Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.
E A Fagan, A L Eddleston.
Gut, 1987 Feb 01; 28(2). PMID: 3549471    Free PMC article.
New properties and roles for eosinophils in disease: discussion paper.
C J Spry.
J R Soc Med, 1985 Oct 01; 78(10). PMID: 3900398    Free PMC article.
Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection.
H Teppler, G Kaplan, +3 authors, Z A Cohn.
J Exp Med, 1993 Feb 01; 177(2). PMID: 8093894    Free PMC article.
The intrapleural administration of recombinant interleukin-2 (rIL-2) to patients with malignant pleural effusion: clinical trials.
H Suzuki, S Abo, +2 authors, K Izumi.
Surg Today, 1993 Jan 01; 23(12). PMID: 8118118
Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement.
A Kinter, A S Fauci.
Immunol Res, 1996 Jan 01; 15(1). PMID: 8739561
Noninvasive imaging of cell-mediated therapy for treatment of cancer.
Elizabeth J Akins, Purnima Dubey.
J Nucl Med, 2008 Jul 01; 49 Suppl 2. PMID: 18523073    Free PMC article.
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Stephanie R Jackson, Jinyun Yuan, Ryan M Teague.
Immunotherapy, 2014 Oct 08; 6(7). PMID: 25290416    Free PMC article.
IL-2 and Beyond in Cancer Immunotherapy.
John M Wrangle, Alicia Patterson, +7 authors, Mark P Rubinstein.
J Interferon Cytokine Res, 2018 Feb 15; 38(2). PMID: 29443657    Free PMC article.
Switchable assembly and function of antibody complexes in vivo using a small molecule.
Alexander J Martinko, Erin F Simonds, +9 authors, Zachary B Hill.
Proc Natl Acad Sci U S A, 2022 Feb 26; 119(9). PMID: 35210365    Free PMC article.